SCHEMBL14486622

SCHEMBL14486622

COc1cc(SCc2ccccc2)cnc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCK P35557 3/20 0.46
▸ RAB9A P51151 3/20 0.43
▸ SCN9A Q15858 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ EGFR P00533 2/20 0.42
▸ ELANE P08246 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ GPBAR1 Q8TDU6 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ PIK3CG P48736 1/20 0.40
▸ METAP2 P50579 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ MCL1 Q07820 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ PIK3CA P42336 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14486608 0.87 MAPT (0.45) RAB9AL3MBTL1ALDH1A1KMT2AGPBAR1
SCHEMBL14486022 0.87 MAPT (0.42) GCKRAB9AL3MBTL1ALDH1A1KMT2A
SCHEMBL14486281 0.87 ABCB1 (0.44) EGFRALDH1A1KMT2AMAPTLMNA
SCHEMBL14485742 0.86 L3MBTL1 (0.48) GCKRAB9AL3MBTL1EGFRALDH1A1
SCHEMBL14486725 0.86 MEN1 (0.54) RAB9AL3MBTL1ALDH1A1KMT2ANPC1
SCHEMBL14485803 0.85 MAPT (0.44) RAB9AL3MBTL1ALDH1A1KMT2AMAPT
SCHEMBL14486615 0.83 PIK3CG (0.44) RAB9AL3MBTL1ALDH1A1KMT2ANPC1
SCHEMBL14486647 0.82 RAB9A (0.47) RAB9AL3MBTL1ALDH1A1KMT2AMAPT
SCHEMBL14486460 0.81 MAPT (0.46) RAB9AL3MBTL1ALDH1A1KMT2AGPBAR1
SCHEMBL26647224 0.79 KMT2A (0.43) GCKRAB9AELANEALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2729449-B1 5- OR 6 - SUBSTITUTED 3 - HYDROXY - 2 ( 1H) - PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAIN TAKEDA PHARMACEUTICALS CO (JP) 2017-10-18 — — EP disclosed
EP-2729449-B1 5- OR 6 - SUBSTITUTED 3 - HYDROXY - 2 ( 1H) - PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAIN TAKEDA PHARMACEUTICALS CO (JP) 2017-10-18 — — EP disclosed
US-9180122-B2 5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-10 — — US disclosed
US-9180122-B2 5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-10 — — US disclosed
US-9180122-B2 5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-10 — — US disclosed
US-20140243353-A1 5- OR 6-SUBSTITUTED 3-HYDROXY-2(1H)-PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAID TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-28 — — US disclosed
US-20140243353-A1 5- OR 6-SUBSTITUTED 3-HYDROXY-2(1H)-PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAID TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-28 — — US disclosed
US-20140243353-A1 5- OR 6-SUBSTITUTED 3-HYDROXY-2(1H)-PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAID TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-28 — — US disclosed
EP-2729449-A1 5- OR 6 - SUBSTITUTED 3 - HYDROXY - 2 ( 1H) - PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAIN Takeda Pharmaceutical Company Limited (JP) 2014-05-14 — — EP disclosed
WO-2013004996-A1 5- OR 6 - SUBSTITUTED 3 - HYDROXY - 2 ( 1H) - PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAIN TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-10 — — WO disclosed
WO-2013004996-A1 5- OR 6 - SUBSTITUTED 3 - HYDROXY - 2 ( 1H) - PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAIN TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243353-A1 5- OR 6-SUBSTITUTED 3-HYDROXY-2(1H)-PYRIDINONES AS D-AMINO ACID OXIDASE (DAAO) INHIBITORS IN THERAPY OF DISEASES SUCH AS SCHIZOPHRENIA, COGNITIVE DISORDER AND PAID DAO, DDO, HAO1 GCK 1865/4885RAB9A 868/4885SCN9A 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback